Generian Pharmaceuticals FcRn inhibitor

Generian Pharmaceuticals is developing an orally bioavailable small molecule inhibitor of the neonatal Fc receptor (FcRn) for the treatment of antibody-mediated autoimmune diseases. The therapeutic mechanism involves blocking the FcRn-mediated recycling of Immunoglobulin G (IgG), which leads to the depletion of pathogenic autoantibodies in circulation. This program, developed in collaboration with Astellas Pharma (via Mitobridge), aims to provide a small molecule alternative to existing biologic FcRn inhibitors, potentially offering improved convenience through oral administration. The asset is currently in preclinical development and represents a novel approach in the FcRn inhibitor landscape, which is currently dominated by monoclonal antibodies and Fc fragments.

Other names

Generian Pharmaceuticals-FcRn (neonatal Fc receptor)-small molecule-antibody-mediated autoimmune diseaseFcRn small molecule inhibitor (Generian Pharmaceuticals)